Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest CSL Limited Stories

2011-03-19 11:45:00

KING OF PRUSSIA, Pa., March 19, 2011 /PRNewswire/ -- CSL Behring today announced the development of an innovative pharmacokinetic (PK) model that allows the absorption, distribution, metabolism, and elimination of subcutaneous (SC) immunoglobulin G (IgG) following administration to be simulated with a high degree of accuracy and precision. The new PK model provides a novel means of simulating the mechanism by which SC IgG is transported after it is injected into the subcutaneous tissue....

2011-02-28 07:00:00

PARIS, Feb. 28, 2011 /PRNewswire/ -- CSL Behring announces a special edition of its Key Issues Dialogue series released in conjunction with Rare Disease Day 2011, an international event to raise awareness of rare diseases and their impact on people's lives. The Dialogue spanned two continents and provided a platform for sharing and exploring important information and ideas for patients, caregivers and healthcare providers. (Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO )...

2011-02-23 16:00:00

RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2011 /PRNewswire/ -- Talecris Biotherapeutics Holdings Corp. ("Talecris") (Nasdaq: TLCR) today announced its financial results for the three and twelve months ended December 31, 2010 and filed its Form 10-K with the U.S. Securities and Exchange Commission (SEC). Fourth quarter 2010 net revenue increased by $20.7 million or 5.3% to $410.8 million from $390.1 million in the fourth quarter of 2009. Higher revenues from Talecris' principal products...

2011-02-18 14:57:00

KING OF PRUSSIA, Pa., Feb. 18, 2011 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact(TM), Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S....

2011-02-16 07:00:00

KING OF PRUSSIA, Pa. and MONTREAL, Feb. 16, 2011 /PRNewswire/ -- As a means of aiding the World Federation of Hemophilia's (WFH) progress in improving the diagnosis and treatment of hemophilia in developing countries through its Global Alliance for Progress (GAP) program, CSL Behring has committed to donating more factor VIII concentrate (FVIII) to WFH. The donated product will be used in South America, Thailand, the Philippines, parts of eastern Europe, parts of the Middle East, and in...

2011-01-27 13:40:00

MARBURG, Germany, Jan. 27, 2011 /PRNewswire/ -- CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia. CSL Behring completed a European Mutual Recognition Procedure (MRP) for Berinert for...

2011-01-20 08:00:00

KING OF PRUSSIA, Pa., Jan. 20, 2011 /PRNewswire/ -- CSL Behring, a global leader in the plasma protein biotherapies industry and a subsidiary of CSL Limited (ASX:CSL), has awarded advocacy grants totaling almost $100,000 to six patient organizations through the Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations committed to helping people who use plasma-derived or recombinant therapies to manage rare and serious...

2010-12-06 07:30:00

SANTA BARBARA, Calif., Dec. 6, 2010 /PRNewswire/ -- Direct Relief International announced today that CSL Behring has donated critically needed medical supplies to assist cholera patients in Haiti. The products will be used at Justinian University Hospital (JUH) in Cap-Haitien. JUH is the main public hospital for the entire northern sector of the country; the I.V. solutions and supplies will also be distributed to the numerous cholera treatment units (CTUs) that have been established in the...

2010-12-01 07:30:00

KING OF PRUSSIA, Pa., Dec. 1, 2010 /PRNewswire/ -- CSL Behring announced today the availability of the next generation HeliTrax® System as part of a specially designed software platform for Apple's iPhone®, iPod touch®, or iPad(TM) devices. This enhanced system is designed to improve therapy management for people with hemophilia A who use CSL Behring's recombinant factor VIII (rFVIII). The new HeliTrax software is designed with an...

2010-11-09 12:00:00

LANSING, Mich., Nov. 9, 2010 /PRNewswire/ -- Bringing awareness to the need for early detection of a genetic disorder that can cause permanent and even fatal organ damage is the main theme of Alpha-1 Antitrypsin Deficiency Month in Michigan. The condition, known as Alpha-1, affects the lungs and liver in children and adults. Today representatives of the Alpha-1 Association, Michigan doctors who treat and advocate for patients with the disease and CSL Behring joined Governor Jennifer M....